


wherein

R₁ is C₁-C₆ alkyl; C₃-C₇ cycloalkyl; or unsubstituted or optionally substituted phenyl having the phenyl substituents halogen, C₁-C₆ alkyl, cyano or C₁-C₃ perfluoroalkyl;

R₂ is unsubstituted or optionally substituted phenyl having the phenyl substituents cyano; acetyl; or unsubstituted or optionally substituted amino having the amino substituents C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or acetyl;


R₃ is unsubstituted or optionally substituted C₁-C₆ alkyl or C₃-C₇ cycloalkyl having the alkyl or cycloalkyl substituents halogen; perfluoroalkyl; unsubstituted or optionally substituted amino having the amino substituents C₁-C₆ alkyl, C₃-C₇ cycloalkyl, or acetyl; hydroxyl; C₁-C₃ alkoxy; protected hydroxyl; carboxyl; or C₁-C₃ alkoxycarbonyl;

R₄ and R₅ are independently hydrogen; C₁-C₆ alkyl; C₁-C₃ cycloalkyl; or




wherein n = 0 or 1 and R₆, R₇, R₈, R₉ & R₁₀ are independently selected from hydrogen; halogen; hydroxyl; protected hydroxyl; C₁-C₆ alkoxy; unsubstituted or optionally substituted C₁-C₆ alkyl having the alkyl substituents hydroxyl or protected hydroxyl; unsubstituted or optionally substituted amino having the amino substituents SO₂ R₁₁, COR₁₁, CONH R₁₁, wherein R₁₁ is C₁-C₆ alkyl, or

aryl; cyano; acetyl; trifluoromethyl; C₁-C₆ alkoxy carbonyl; or two successive positions of the phenyl ring substituted by an unsubstituted or optionally substituted methylene dioxy group having the structure



wherein R₁₂ is C₁-C₃ alkyl; with the proviso that when n=0 at least one of R₆, R₇, R₈, R₉ & R₁₀ is hydroxyl or protected hydroxyl, with the further proviso that if only one of R₆, R₇, R₈, R₉ & R₁₀ is hydroxyl or protected hydroxyl, then at least one of the other substituents is not hydrogen.

wherein Y is



including the tautomers, racemates, pure enantiomers and diastereoisomers, N-oxides, or solvates of the compound of Formula I.

66. (Amended) A method of inhibiting cholesterol biosynthesis in a patient in need of such treatment ~~by comprising~~ administering a pharmaceutical composition as ~~defined by claim 79~~, wherein the composition comprises a hypocholesterolemic amount of a compound selected from

7-[3-(2,4-dimethoxyphenylcarbamoyl)-5-(4-fluorophenyl)-2-(1-methylethyl)-4-phenyl-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[3-(2-methoxy-4-hydroxyphenylcarbamoyl)-5-(4-fluorophenyl)-2-(1-methylethyl)-4-phenyl-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[3-(2,4-dihydroxyphenylcarbamoyl)-5-(4-fluorophenyl)-2-(1-methylethyl)-4-phenyl-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[2-cyclopropyl-3-(2,4-dimethoxyphenylcarbamoyl)-5-(4-fluorophenyl)-4-phenyl-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[3-(2,4-dimethoxyphenylcarbamoyl)-4,5-diphenyl-5-(4-fluorophenyl)-2-(1-methylethyl)-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[4,5-bis(4-fluorophenyl)-3-(2,4-dimethoxyphenylcarbamoyl)-2-(1-methylethyl)-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[3-(3,5-dimethoxyphenylcarbamoyl)-5-(4-fluorophenyl)-2-(1-methylethyl)-4-phenyl-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[3-(3,4-dimethoxyphenylcarbamoyl)-5-(4-fluorophenyl)-2-(1-methylethyl)-4-phenyl-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[4,5-bis(4-fluorophenyl)-2-cyclopropyl-3-(2,4-dimethoxyphenylcarbamoyl)-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[5-(3,4-difluorophenyl)-3-(2,4-dihydroxyphenylcarbamoyl)-2-(1-methylethyl)-4-(4-fluorophenyl)-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[2-cyclopropyl-5-(3,4-difluorophenyl)-3-(2,4-dihydroxyphenylcarbamoyl)-4-(4-fluorophenyl)-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[5-(3,4-difluorophenyl)-3-(2,4-dihydroxyphenylcarbamoyl)-2-(1-methylethyl)-4-phenyl-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;

7-[5-(3,4-difluorophenyl)-3-(2,4-dimethoxycarbamoyl)-4-(4-fluorophenyl)-2-(1-methylethyl)-pyrrol-1-yl]-3R, 5R-dihydroxy-heptanoic acid calcium salt;